A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Saad, F
  • Hotte, Sebastien
  • North, SA
  • Eigl, BJ
  • Chi, KN
  • Czaykowski, P
  • Polllak, M
  • Wood, L
  • Winquist, E

publication date

  • May 20, 2008